Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNLI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDenali regains full rights to DNL593 as Takeda terminates collaboration agreement
Filed April 3, 2026 · Period ending April 3, 2026 · ~1 min read
Key Changes
-
high
Takeda terminated the 2018 collaboration agreement for DNL593, effective 60 days from April 3, 2026. All development and commercialization rights revert to Denali with no further financial obligations.
Item 1.02 verify on EDGAR → -
medium
Takeda cited strategic considerations for the termination, explicitly stating the decision was not related to efficacy or safety data from the DNL593 program.
Item 1.02 verify on EDGAR → -
high
Denali now has full control over DNL593's future development strategy and potential commercialization without partnership constraints or revenue-sharing obligations.
Item 1.02 verify on EDGAR →
Summary
Denali Therapeutics received notice that Takeda is terminating their eight-year collaboration on DNL593, a drug candidate targeting progranulin deficiency. The partnership, established in 2018, involved joint development and commercialization plans. Takeda emphasized the decision reflects its own strategic priorities rather than concerns about the drug's clinical profile.
For Denali shareholders, this represents both opportunity and challenge. The company regains complete control over a potentially valuable asset without ongoing obligations to share future revenues or development costs with Takeda. However, Denali will now need to fund DNL593 development independently and may need to seek alternative partnerships or financing.
Investors should watch for Denali's next steps: whether management provides updated clinical timelines, announces plans to advance DNL593 alone, or seeks a new partner. The company's cash position and ability to fund the program through key milestones will be critical factors in determining whether this termination ultimately benefits shareholders.
Section-by-Section Diff
Event · Item 1.02 — Termination of a Material Definitive Agreement
Item 1.02 — Termination of a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Takeda has terminated the 2018 collaboration agreement for DNL593, a drug candidate the companies were jointly developing and planning to commercialize. The termination notice was received April 3, 2026, and will become effective 60 days later.
Added in current filing · verify on EDGAR →
The decision was driven by strategic considerations and is not related to efficacy or safety data.
Takeda stated the termination was based on strategic considerations rather than problems with the drug's efficacy or safety profile. This suggests the decision reflects Takeda's portfolio priorities rather than clinical concerns about DNL593.
Added in current filing · verify on EDGAR →
The termination will become effective 60 days following the notice date, at which time all rights in the DNL593 program will revert to Denali. Following termination, Denali will have no further financial obligations to Takeda.
All rights to DNL593 will return to Denali when the termination becomes effective, and Denali will have no ongoing financial obligations to Takeda. This gives Denali full control over the program's future development and commercialization strategy.
Event · Item 9.01 — Financial Statements and Exhibits
Denali Therapeutics filed an 8-K attaching a press release dated April 3, 2026; no material business event disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit No.Description
99.1 Press Release dated April 3, 2026
The 8-K attaches a press release dated April 3, 2026 as Exhibit 99.1. The filing body provides no details about the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K text alone. The filing is marked as furnished rather than filed under Item 9.01.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify